Endo Int\'l (ENDP) Acquires Natesto Gel Rights from Trimel BioPharma

November 24, 2014 7:02 AM EST Send to a Friend
Endo Int\'l (NASDAQ: ENDP) the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login